Skip to main content

Apellis Pharmaceuticals, Inc. (APLS)

NASDAQ: APLS · IEX Real-Time Price · USD
43.01 1.58 (3.81%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap4.19B
Revenue (ttm)256.27M
Net Income (ttm)-520.16M
Shares Out97.36M
EPS (ttm)-6.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume776,368
Open42.99
Previous Close41.43
Day's Range40.92 - 43.24
52-Week Range27.50 - 73.00
Beta1.56
AnalystsBuy
Price Target68.75 (+59.8%)
Earnings DateNov 8, 2021

About APLS

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous n...

IndustryBiotechnology
IPO DateNov 9, 2017
CEOCedric Francois
Employees486
Stock ExchangeNASDAQ
Ticker SymbolAPLS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for APLS stock is "Buy." The 12-month stock price forecast is 68.75, which is an increase of 59.85% from the latest price.

Price Target
$68.75
(59.85% upside)
Analyst Consensus: Buy

News

Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will presen...

1 week ago - GlobeNewsWire

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase ...

WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously...

2 weeks ago - GlobeNewsWire

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced an unde...

3 weeks ago - GlobeNewsWire

Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic ...

WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that it received formal, written feedback from the U.S. Food and Drug Administration (FDA) ...

3 weeks ago - GlobeNewsWire

Apellis' (APLS) Q3 Loss Widens, Revenues Surpass Estimates

Apellis (APLS) reports wider-than-expected loss for the third quarter of 2021 while revenues surpass expectations.

4 weeks ago - Zacks Investment Research

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -31.79% and 143.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for...

1 month ago - Zacks Investment Research

Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results

WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its third quarter 2021 financ...

1 month ago - GlobeNewsWire

Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 202...

WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that five abstracts were acce...

1 month ago - GlobeNewsWire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company ...

1 month ago - GlobeNewsWire

Apellis Pharmaceuticals to Host Conference Call on November 8, 2021 to Discuss Third Quarter 2021 Financial Results

WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company ...

1 month ago - GlobeNewsWire

Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Apellis Pharmaceuticals, Inc. (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised)

The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

1 month ago - Zacks Investment Research

Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug

The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

1 month ago - Zacks Investment Research

Aspaveli® (pegcetacoplan) receives positive CHMP opinion for treatment of PNH

STOCKHOLM, Oct. 15, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announce today that the Committee for Medicinal Products f...

1 month ago - PRNewsWire

Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH

WALTHAM, Mass. and STOCKHOLM, Sweden, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that the Co...

1 month ago - GlobeNewsWire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company a...

2 months ago - GlobeNewsWire

Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting

WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that detailed data from the ...

2 months ago - GlobeNewsWire

Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company...

2 months ago - GlobeNewsWire

Apellis (APLS) Down on Mixed Data From Studies on GA Candidate

Apellis (APLS) posts mixed top-line data from the phase III DERBY and OAKS studies testing pegcetacoplan in adults with geographic atrophy secondary to age-related macular degeneration. Stock falls.

2 months ago - Zacks Investment Research

APLS Stock: The Trial Results That Have Apellis Pharmaceuticals Plunging Today

Here's why investors are in full selloff mode today with APLS stock on Apellis Pharmaceuticals' latest clinical trial results. The post APLS Stock: The Trial Results That Have Apellis Pharmaceuticals Pl...

2 months ago - InvestorPlace

Why Apellis Pharmaceutical Shares Are Plunging Today

Apellis Pharmaceuticals Inc (NASDAQ: APLS) is trading lower Friday after the company announced its Phase 3 DERBY study in geographic atrophy did not meet the primary endpoint of GA lesion growth. DERBY ...

2 months ago - Benzinga

Here's Why Apellis Pharmaceuticals Is Getting Hammered Today

Conflicting clinical trial results for the company's lead candidate are to blame.

2 months ago - The Motley Fool

Apellis Unveils Mixed Results For Eye Disorder Drug, But Still Hopes To Pass FDA Finish Line

Apellis Pharmaceuticals Inc's (NASDAQ: APLS) pegcetacoplan posted mixed results in two Phase 3 trials in 1,258 geographic atrophy (GA).  Despite the mixed showing, CEO Cedric Francois thinks the candida...

2 months ago - Benzinga

Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit...

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today reported top-line results from the Pha...

2 months ago - GlobeNewsWire

Apellis Pharmaceuticals, Inc. (APLS) Down 6.8% Since Last Earnings Report: Can It Rebound?

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research